InspireMD, Inc. — Form 8-K
Filed September 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
InspireMD amended warrant agreements with existing holders on September 21, 2026. Series J warrants: 4.8M shares (50% of participating holders' stake) amended to exercise price $0.7674/share and termination date May 15, 2028 or 20 trading days post-FDA approval of CGuard Prime 80 cm (whichever earlier); remaining 50% unchanged at $1.3827/share. Series K warrants: 9.5M shares fully amended to same $0.7674 exercise price and FDA-approval termination trigger. No new warrants issued. Potential gross proceeds if fully exercised: ~$11M. Exercise prices reflect September 18, 2026 Nasdaq closing price.
Why this rating
Warrant amendments are routine capital structuring, $11M potential proceeds is ~18% of $60.9M market cap—meaningful but not transformational. No new dilution, FDA approval timeline already public. Aligns warrant incentives with near-term milestone.
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.